Department of Interventional Cardiology, S Ambrogio Clinical Institute, Milan, Italy.
QJM. 2010 Jun;103(6):367-77. doi: 10.1093/qjmed/hcq017. Epub 2010 Mar 7.
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate 2 receptor. They have been shown to significantly reduce platelet activity exerting an important role in those clinical settings in which such an effect is beneficial. Ticlopidine was first to be introduced several years ago but it was quickly replaced by clopidogrel as it had a better risk/benefit profile. Recently, prasugrel has been developed and tested in several ex vivo studies and clinical trials showing able to provide a more powerful antiplatelet effect at the expense of a higher risk of bleeding complications. Great debate rose around its recent approval in the US as well as in Europe. This review aims at exploring the development and available clinical data of this third-generation thienopyridine while discussing its practical implementation in routine practice.
噻吩并吡啶类药物是一类靶向血小板二磷酸腺苷 2 受体的药物。它们已被证明能显著降低血小板活性，在那些有益于这种作用的临床环境中发挥重要作用。噻氯匹定几年前首先被引入，但很快被氯吡格雷取代，因为它具有更好的风险/效益比。最近，普拉格雷已在几项体外研究和临床试验中进行了开发和测试，结果表明，它能够提供更强大的抗血小板作用，但其出血并发症的风险更高。最近在美国和欧洲批准使用该药引起了激烈的争论。这篇综述旨在探讨第三代噻吩并吡啶的发展和现有临床数据，同时讨论其在常规实践中的实际应用。
